Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 174

Similar articles for PubMed (Select 23558310)

1.

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.

Bos M, Gardizi M, Schildhaus HU, Heukamp LC, Geist T, Kaminsky B, Zander T, Nogova L, Scheffler M, Dietlein M, Kobe C, Holstein A, Maintz D, Büttner R, Wolf J.

Lung Cancer. 2013 Jul;81(1):142-3. doi: 10.1016/j.lungcan.2013.02.018. Epub 2013 Apr 1.

PMID:
23558310
2.

ROS1 rearrangements define a unique molecular class of lung cancers.

Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ.

J Clin Oncol. 2012 Mar 10;30(8):863-70. doi: 10.1200/JCO.2011.35.6345. Epub 2012 Jan 3.

3.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ.

N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27.

PMID:
25264305
4.
5.

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, Wilner KD, Lockerman EL, Khan TM, Mahmood S, Gainor JF, Digumarthy SR, Stone JR, Mino-Kenudson M, Christensen JG, Iafrate AJ, Engelman JA, Shaw AT.

N Engl J Med. 2013 Jun 20;368(25):2395-401. doi: 10.1056/NEJMoa1215530. Epub 2013 Jun 1.

6.

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.

Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC.

Ann Oncol. 2013 Sep;24(9):2364-70. doi: 10.1093/annonc/mdt220. Epub 2013 Jun 19.

7.

A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.

Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, Ahn MJ, Park K.

J Thorac Oncol. 2012 Dec;7(12):e36-8. doi: 10.1097/JTO.0b013e318274694e. No abstract available.

PMID:
23154564
8.

Mouse model for ROS1-rearranged lung cancer.

Arai Y, Totoki Y, Takahashi H, Nakamura H, Hama N, Kohno T, Tsuta K, Yoshida A, Asamura H, Mutoh M, Hosoda F, Tsuda H, Shibata T.

PLoS One. 2013;8(2):e56010. doi: 10.1371/journal.pone.0056010. Epub 2013 Feb 13.

9.

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma.

Gennatas S, Stanway SJ, Thomas R, Min T, Shah R, O'Brien ME, Popat S.

BMC Cancer. 2013 Apr 26;13:207. doi: 10.1186/1471-2407-13-207.

10.

Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.

Kim SJ, Kim DW, Kim TM, Lee SH, Heo DS, Bang YJ.

J Clin Oncol. 2012 Jun 1;30(16):e147-50. doi: 10.1200/JCO.2011.39.9766. Epub 2012 Apr 16. No abstract available.

11.

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ.

Oncologist. 2012;17(11):1351-75. doi: 10.1634/theoncologist.2012-0311. Epub 2012 Sep 18. Review.

12.

[A new target in non-small cell lung cancer: ROS1 fusion gene].

Cai WJ, Su B.

Zhonghua Zhong Liu Za Zhi. 2013 Jan;35(1):1-4. doi: 10.3760/cma.j.issn.0253-3766.2013.01.001. Review. Chinese. No abstract available.

PMID:
23648291
13.

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.

Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ.

J Thorac Oncol. 2010 Dec;5(12):2044-6. doi: 10.1097/JTO.0b013e318200f9ff. No abstract available.

PMID:
21102269
14.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Arnaoutakis K.

N Engl J Med. 2015 Feb 12;372(7):683. doi: 10.1056/NEJMc1415359#SA1. No abstract available.

PMID:
25671265
15.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Shaw AT, Solomon BJ.

N Engl J Med. 2015 Feb 12;372(7):683-4. doi: 10.1056/NEJMc1415359. No abstract available.

16.

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Gerlinger M, Norton L, Swanton C.

N Engl J Med. 2013 Sep 19;369(12):1172-3. doi: 10.1056/NEJMc1309091#SA1. No abstract available.

PMID:
24047073
17.

Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.

Kaneda H, Okamoto I, Nakagawa K.

J Thorac Oncol. 2013 Apr;8(4):e32-3. doi: 10.1097/JTO.0b013e3182843771. No abstract available.

PMID:
23486271
18.

Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.

Pilotto S, Bria E, Peretti U, Massari F, Garassino M, Pelosi G, Tortora G.

J Thorac Oncol. 2013 Dec;8(12):e105-6. doi: 10.1097/JTO.0b013e3182a00e37. No abstract available.

PMID:
24389444
19.

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C.

Target Oncol. 2013 Mar;8(1):55-67. doi: 10.1007/s11523-012-0250-9. Epub 2013 Jan 17. Review.

PMID:
23325296
20.

[Therapeutic impact of molecular diagnosis in metastatic non-small cell lung cancer: targeted therapies in 2013].

Pecuchet N, Bigot F, Henni M, Fabre E.

Rev Pneumol Clin. 2014 Feb-Apr;70(1-2):38-46. doi: 10.1016/j.pneumo.2013.12.005. Epub 2014 Feb 22. Review. French.

PMID:
24566025
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk